Literature DB >> 6100422

Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery.

L Kager, L Liljeqvist, A S Malmborg, C E Nord, R Pieper.   

Abstract

The influence of a combination of ampicillin and a beta-lactamase inhibitor, sulbactam, on colonic bacterial flora was studied in patients undergoing colorectal surgery. Drug concentrations were determined in serum, intestinal mucosa, and feces. The results of the drug concentrations were correlated with changes in the numbers of aerobic and anaerobic bacterial bowel flora. Ampicillin and sulbactam were given intravenously to 21 patients in 500-mg doses of each drug every 8 h for 2 days. The first dose was given when anesthesia was begun. The concentrations of ampicillin in serum were significantly higher (0.01 greater than P greater than 0.001) than those of sulbactam. In contrast, at all time intervals, the concentrations of sulbactam in intestinal mucosa were significantly higher than those of ampicillin (0.05 greater than P greater than 0.01). The serum half-life of the two drugs was the same at 2.2 h. After one dose of the antibiotics, sulbactam was detectable in the feces of four patients, and ampicillin was detectable in the feces of 11 patients. During the 2 days of ampicillin and sulbactam prophylaxis, no measurable decrease occurred in the anaerobic flora of the bowel; a mean decrease of 3 logs occurred in the anaerobic bowel flora. The results of this study show that ampicillin and sulbactam prophylaxis had a greater effect on the anaerobic bowel flora than on the aerobic bowel flora. In light of the in vitro spectrum of ampicillin and sulbactam activity, it was surprising that bowel aerobic flora was unchanged.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6100422      PMCID: PMC183712          DOI: 10.1128/AAC.22.2.208

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Description and classification of the newer cephalosporins and their relationships with the established compounds.

Authors:  C H O'Callaghan
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

2.  WOUND SEPSIS AFTER CLEAN OPERATIONS.

Authors:  U LJUNGQVIST
Journal:  Lancet       Date:  1964-05-16       Impact factor: 79.321

3.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

4.  Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis.

Authors:  B Olsson; K Dornbusch; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

5.  Antimicrobial prophylaxis to prevent mixed bacterial infection.

Authors:  B F Polk
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

6.  Comparative inhibition beta-lactamases by novel beta-lactam compounds.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery.

Authors:  L Kager; L Liljeqvist; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

8.  Antibiotic prophylaxis with cefoxitin in colorectal surgery: effect on the colon microflora and septic complications--a clinical model for prediction of the benefit and risks in using a new antibiotic in prophylaxis.

Authors:  L Kager; I Ljungdahl; A S Malmborg; C E Nord; R Pieper; P Dahlgren
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

  8 in total
  8 in total

Review 1.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

3.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Concentrations of ampicillin plus sulbactam in serum and intestinal mucosa and effects on the colonic microflora in patients undergoing colorectal surgery.

Authors:  L Kager; A S Malmborg; S Sjöstedt; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

5.  Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

6.  The effect of piperacillin prophylaxis on the colonic microflora In patients undergoing colorectal surgery.

Authors:  L Kager; A S Malmborg; C E Nord; S Sjöstedt
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

7.  In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

Authors:  H M Wexler; B Harris; W T Carter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.

Authors:  P Van der Auwera; B Scorneaux
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.